Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer

Zhao, Peng; Bu, Xiaocui; Wei, Xiaofang; Sun, Weihong; Xie, Xihe; Li, Changyou; Guo, Qingming; Zhu, Danni; Wei, Xiaoqiang; Gao, Daiqing

doi:10.1016/j.intimp.2015.02.010

Cited by 40 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…202 Conversely, a T-cell polarization skewed toward an immunosuppressive Th2 phenotype was found to reduce the therapeutic efficacy of DC-CIK co-administration in NSCLC patients. 207 Finally, increased plasma levels of proinflammatory cytokines like IL-6 and IL-8 negatively correlated with overall survival following DC-based vaccination in pancreatic ductal adenocarcinoma patients. 236 Collectively, these studies highlight that DC-based vaccines are well-tolerated by cancer patients, with mild flu-like symptoms and local irritation at the injection site being the most common side effects, and can elicit antitumor immune response of therapeutic value.…”

Section: Completed Clinical Trialsmentioning

confidence: 97%

“…1) involved autologous DCs exposed to autologous tumor-derived RNA, 196 tumor-cell lysates, [197][198][199][200][201][202][203] autologous tumor stem cell lysates, 204 self-renewing and proliferating autologous tumor cells, 205 allogeneic cancer cell line lysates, [206][207][208] TAAs or TAA-derived peptides [209][210][211][212][213][214][215][216][217][218] or a combination thereof. 219 Most clinical studies based on the latter approach preferred melanoma-associated differentiation antigens including premelanosome protein (PMEL; also known as gp100), antigens belonging to the melanoma antigen gene (MAGE) family, tyrosinase (TYR) and Melan-A (MLANA; also known as MART1) (Fig.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

“…230 Regarding the distribution across different cancer types ( Fig. 1), patients harboring melanoma were most commonly enrolled in these trials, 186,196,198,205,213,221,223,227,[231][232][233][234] followed by patients with prostate cancer, 206,208,212,215 glioma or glioblastoma (GBM), 185,197,202,219 hepatocellular carcinoma, 204,211,220 non-small cell lung carcinoma (NSCLC), 207,214,230 renal cell carcinoma (RCC), 201,203 esophageal carcinoma, 216,226 and pancreatic ductal adenocarcinoma, 209,217 among others. Of note, only two trials included a wide range of advanced solid tumors refractory to previous treatments.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

See 2 more Smart Citations

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" (typically a combination of pro-inflammatory cytokines and Toll-like receptor agonists), followed by DC reintroduction into patients. DC vaccines have been documented to (re)activate tumor-specific T cells in both preclinical and clinical settings. There is considerable clinical interest in combining DC-based anticancer vaccines with T cell-targeting immunotherapies. This reflects the established capacity of DC-based vaccines to generate a pool of TAA-specific effector T cells and facilitate their infiltration into the tumor bed. In this Trial Watch, we survey the latest trends in the preclinical and clinical development of DC-based anticancer therapeutics. We also highlight how the emergence of immune checkpoint blockers and adoptive T-cell transfer-based approaches has modified the clinical niche for DC-based vaccines within the wide cancer immunotherapy landscape.

show abstract

Section: Completed Clinical Trialsmentioning

confidence: 97%

Section: Completed Clinical Trialsmentioning

confidence: 99%

Section: Completed Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Other studies suggest that the cytotoxicity of CIK cells can be enhanced and improved by DC vaccination and when transfected with IL-2 gene or activated by Retro Nectin, these CIK cells demonstrate a higher proliferation rate and efficient cytotoxic activity. 54,56,[58][59][60][62][63][64]67,68,72,75,84 In general, all these published studies have demonstrated that CIK cell-based immunotherapy utilizes the body's natural ability to eliminate tumor cells by stimulating and restoring the ability of the immune system to recognize and kill tumor cells. In contrast to conventional therapeutic strategies, the application of CIK cells is associated with minimal side effects and no severe adverse events have been reported.…”

Section: Clinical Usementioning

confidence: 99%

Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application

Meng

Zhong

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Cell-based immunotherapy holds promise in the quest for the treatment of cancer, having potential synergy with surgery, chemotherapy and radiotherapy. As a novel approach for adoptive cell-based immunotherapy, cytokine-induced killer (CIK) cells have moved from the 'bench to bedside'. CIK cells are a heterogeneous subset of ex-vitro expanded, polyclonal T-effector cells with both natural killer (NK) and Tcell properties, which present potent non-major histocompatibility complex-restricted cytotoxicity against a variety of tumor target cells. Initial clinical studies on CIK cell therapy have provided encouraging results and revealed synergistic antitumor effects when combined with standard therapeutic procedures. At the same time, issues such as inadequate quality control and quantity of CIK cells as well as exaggerated propaganda were continuously emerging. Thus, the Ministry of Health in China stopped CIK cell therapy in May 2016, which was a major setback for the innovation of CIK cell-based immunotherapy. Thus, it is very important to modify technical criteria to develop a standardized operation procedure (SOP) and standardized system for evaluating antitumor efficacy in a safe way.

show abstract

“…In addition, CIKs can regulate and generally enhance the immune functions in patients with several types of cancer (7). In previous years, a large number of studies (5,14,15) have shown that DCs could activate CIKs by co-culture on changing the surface molecule expression, increasing cytokine secretion and causing a higher cytolytic capacity (16). The present retrospective study was performed to evaluate the effects and safety of DC-CIK treatment on different types of cancers in patients aged >65 years.…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old

Liu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer

Cited by 40 publications

References 35 publications

Trial watch: Dendritic cell-based anticancer immunotherapy

Trial watch: Dendritic cell-based anticancer immunotherapy

Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application

Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old

Contact Info

Product

Resources

About